Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
By comparison, small bonuses were paid to scientists and doctors. $35 million in bonuses all together were handed out. The head of the criminal investigation division made more than the director of the FBI and the person in charge of revising the bonus system, well, they got the biggest bonus...
The basis of the current affairs of the FDA are not unlike many other stories being told today. We live in a world of transparency, and we are all still getting used to it for that matter, but things don’t fit under the carpet anymore. The old saying of “if it isn’t broke, don’t fix it”...